ATE375786T1 - Chitin-mikropartikel und ihre medizinische verwendung - Google Patents

Chitin-mikropartikel und ihre medizinische verwendung

Info

Publication number
ATE375786T1
ATE375786T1 AT02758543T AT02758543T ATE375786T1 AT E375786 T1 ATE375786 T1 AT E375786T1 AT 02758543 T AT02758543 T AT 02758543T AT 02758543 T AT02758543 T AT 02758543T AT E375786 T1 ATE375786 T1 AT E375786T1
Authority
AT
Austria
Prior art keywords
medical use
chitin microparticles
gamma
treatment
chitin
Prior art date
Application number
AT02758543T
Other languages
English (en)
Inventor
Peter Strong
Original Assignee
Cmp Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120030A external-priority patent/GB0120030D0/en
Priority claimed from GB0206864A external-priority patent/GB0206864D0/en
Application filed by Cmp Therapeutics Ltd filed Critical Cmp Therapeutics Ltd
Application granted granted Critical
Publication of ATE375786T1 publication Critical patent/ATE375786T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02758543T 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung ATE375786T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120030A GB0120030D0 (en) 2001-08-16 2001-08-16 Chitin Microparticles and their medical uses
GB0206864A GB0206864D0 (en) 2002-03-22 2002-03-22 Chitin microparticles and their medical uses

Publications (1)

Publication Number Publication Date
ATE375786T1 true ATE375786T1 (de) 2007-11-15

Family

ID=26246442

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758543T ATE375786T1 (de) 2001-08-16 2002-08-16 Chitin-mikropartikel und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US7498038B2 (de)
EP (1) EP1416916B1 (de)
JP (1) JP2005501845A (de)
CN (1) CN1543338B (de)
AT (1) ATE375786T1 (de)
AU (1) AU2002324124B2 (de)
CA (1) CA2457027C (de)
DE (1) DE60223037T2 (de)
ES (1) ES2295391T3 (de)
PT (1) PT1416916E (de)
WO (1) WO2003015744A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001491B1 (de) 2006-04-05 2016-06-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antiallergische zusammensetzungen
WO2008054892A2 (en) * 2006-06-16 2008-05-08 Florida Atlantic University Chitin micro-particles as an adjuvant
AU2007262845B2 (en) 2006-06-20 2013-07-25 Mucovax Inc. Compositions comprising chitin microparticles and their medical uses
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
WO2008053192A2 (en) 2006-10-30 2008-05-08 Cmp Therapeutics Limited Methods of producing microparticles
CN100531742C (zh) * 2007-01-18 2009-08-26 宁波普爱生物工程有限公司 一种抗肿瘤氨基多糖超细微粒及其制备方法
EP2123261A1 (de) * 2008-05-20 2009-11-25 Stallergenes S.A. Speichelklebende Partikelformulierung zur Induzierung von antigenspezifischer Immuntoleranz
US20110253140A1 (en) * 2008-07-30 2011-10-20 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
US9005899B2 (en) * 2010-04-01 2015-04-14 Mingchi University Of Technology Chitin-induced immune response based method for diagnosing allergic asthma in patients
WO2011135578A1 (en) * 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
AU2011290550B2 (en) * 2010-08-17 2016-04-07 Mucovax Inc. Nutritional compositions comprising chitin microparticles
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
HK1253702A1 (zh) 2015-06-04 2019-06-28 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
JP7062291B2 (ja) * 2016-05-13 2022-05-16 応用酵素医学研究所株式会社 アレルギー発症リスクを予測するためのデータを収集する方法
JP7152785B2 (ja) 2016-10-25 2022-10-13 アモーフィカル リミテッド. 白血病治療のための非晶質炭酸カルシウム
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
US20220317124A1 (en) 2021-04-01 2022-10-06 Becton Dickinson And Company Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5543041A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
JPS5927826A (ja) * 1982-08-10 1984-02-14 Masuko Suzuki 抗感染症剤
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4873092A (en) * 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP2824185B2 (ja) * 1993-03-22 1998-11-11 旭化成工業株式会社 魚類免疫賦活剤
JPH07188291A (ja) * 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
JPH0959164A (ja) * 1995-08-21 1997-03-04 San Five Kk 抗炎症剤
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
ATE216264T1 (de) 1996-07-10 2002-05-15 West Pharm Serv Drug Res Ltd Gentherapiesystem zur zielung des endotheliums
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP4097737B2 (ja) * 1997-04-07 2008-06-11 ユニチカ株式会社 鼻口腔用抗炎症散布剤
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
DE69831421T2 (de) 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
GB9800912D0 (en) 1998-01-17 1998-03-11 Danbiosyst Uk New composition
EA003328B1 (ru) * 1998-04-08 2003-04-24 Эли Лилли Энд Компани Легочная и назальная доставка ралоксифена
ATE326239T1 (de) * 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
JP5124066B2 (ja) 1999-03-24 2013-01-23 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
KR100345466B1 (ko) 1999-10-08 2002-07-26 한국과학기술연구원 콜레라 독소 b 소단위로 표면 수식된 마이크로스피어
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001280934A1 (en) 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
WO2002034287A2 (en) 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
CA2446355A1 (en) 2001-05-03 2002-11-14 The Government Of The United States Of America Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
WO2003086454A1 (en) 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2007262845B2 (en) * 2006-06-20 2013-07-25 Mucovax Inc. Compositions comprising chitin microparticles and their medical uses

Also Published As

Publication number Publication date
US8551501B2 (en) 2013-10-08
WO2003015744A1 (en) 2003-02-27
CA2457027A1 (en) 2003-02-27
US20040234614A1 (en) 2004-11-25
EP1416916B1 (de) 2007-10-17
US20090214666A1 (en) 2009-08-27
US7498038B2 (en) 2009-03-03
ES2295391T3 (es) 2008-04-16
CN1543338A (zh) 2004-11-03
DE60223037T2 (de) 2008-07-24
EP1416916A1 (de) 2004-05-12
DE60223037D1 (de) 2007-11-29
AU2002324124B2 (en) 2007-01-04
CA2457027C (en) 2011-10-11
PT1416916E (pt) 2008-01-25
JP2005501845A (ja) 2005-01-20
CN1543338B (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
KR20030025907A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005000215A3 (en) Methods for treating pain
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
IL184749A0 (en) Anti-interferon gamma antibodies and pharmaceutical compositions containing the same
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
NO20064192L (no) Agonister og antagonister av P28, EB13 og WSX/TCCR til behandling av immunforstyrrelser
MA27998A1 (fr) Nouvelle formulation
PL1622939T3 (pl) Aktywne warianty białka wiążącego IL-18 i ich medyczne zastosowania
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
SE0302304D0 (sv) Novel compounds
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DE602004009414D1 (de) BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN MIT N-2,3,3-TETRAMETHYLBICYCLOi2.2.1öHEPTAN-2-AMINE
DE60042210D1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe